サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1370547

アンチセンスとRNAi治療薬市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アンチセンスとRNAi治療薬市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年10月15日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

市場概要：

世界のアンチセンスとRNAi治療薬市場規模は2022年に15億米ドルに達しました。今後、IMARC Groupは、同市場が2023年から2028年の間に8.3%の成長率（CAGR）を示し、2028年までに25億米ドルに達すると予測しています。

アンチセンス療法は、一本鎖DNAオリゴヌクレオチドによる選択的かつ配列特異的な遺伝子発現阻害です。細胞機能と細胞分裂を制御し、内的・外的ストレスや刺激に対する細胞応答を調節することができます。筋萎縮性側索硬化症やハンチントン病、アルツハイマー病の治療にも用いられます。一方、RNA干渉（RNAi）療法は、二本鎖RNA（dsRNA）によって引き起こされ、dsRNAに応答して一本鎖標的RNAの配列特異的リボ核酸（mRNA）分解を引き起こします。慢性閉塞性肺疾患（COPD）や喘息など、さまざまな呼吸器疾患の治療に用いられています。RNAi療法はまた、病気を引き起こしたり、病気の成長に寄与したりする特定の遺伝子の産生を防ぐのにも役立ちます。

アンチセンスとRNAi治療薬の市場動向：

遺伝性ATTRアミロイドーシスなどの珍しい神経変性疾患を治療するためのアンチセンスとRNAi治療薬に対する需要の高まりは、市場を牽引する重要な要因の一つです。これに加えて、世界中で機能不全に陥った遺伝子による遺伝子発現を調節する疾患管理に対する需要が増加しています。これは、急成長するヘルスケア産業とともに、市場の成長に寄与しています。さらに、主な市場参入企業は、アンチセンス技術に基づく分子を開発するため、研究開発（R&D）活動に幅広く投資しています。また、ドラッグデリバリーを手がける開発業務受託機関（CRO）との提携も進んでおり、市場の成長を後押ししています。さらに、病気の発症を予防し、病気の進行を抑えるためのアンチセンスRNAに対する需要の高まりは、市場にプラスの影響を与えています。これとは別に、がん、ヒト免疫不全ウイルス（HIV）、変異ウイルスによって引き起こされる他の病気などの病気を治したり予防したりする必要性の高まりが、市場の成長を後押ししています。

本レポートで扱う主な質問

  • アンチセンスとRNAi治療薬の世界市場規模は？
  • 2023-2028年のアンチセンスとRNAi治療薬世界市場の予想成長率は？
  • 世界のアンチセンスとRNAi治療薬市場を牽引する主要因は何か？
  • COVID-19が世界のアンチセンスとRNAi治療薬市場に与えた影響は？
  • 技術に基づくアンチセンスとRNAi治療薬の世界市場の内訳は？
  • 投与経路に基づくアンチセンスとRNAi治療薬の世界市場内訳は？
  • アンチセンスとRNAi治療薬の世界市場における主要地域は？
  • 世界のアンチセンスとRNAi治療薬市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 アンチセンスとRNAi治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：技術別

  • RNA干渉
    • 市場動向
    • 主要セグメント
      • siRNA
      • miRNA
    • 市場予測
  • アンチセンスRNA
    • 市場動向
    • 市場予測

第7章 市場内訳：投与経路別

  • 静脈内投与ルート
    • 市場動向
    • 市場予測
  • 皮下投与ルート
    • 市場動向
    • 市場予測
  • 髄腔内ルート
    • 市場動向
    • 市場予測
  • 肺送達
    • 市場動向
    • 市場予測
  • 腹腔内注射
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • オンコロジー
    • 市場動向
    • 市場予測
  • 心血管疾患（CVDs）
    • 市場動向
    • 市場予測
  • 呼吸器疾患
    • 市場動向
    • 市場予測
  • 腎臓疾患
    • 市場動向
    • 市場予測
  • 神経変性疾患
    • 市場動向
    • 市場予測
  • 遺伝性疾患
    • 市場動向
    • 市場予測
  • 感染症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Alnylam Pharmaceuticals Inc.
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals Inc.
    • Benitec Biopharma Ltd.
    • Bio-Path Holdings Inc.
    • Dicerna Pharmaceuticals Inc.（Novo Nordisk A/S）
    • Ionis Pharmaceuticals Inc.
    • OliX Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Sarepta Therapeutics Inc.
    • Silence Therapeutics
    • Sirnaomics Inc.
図表

List of Figures

  • Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2022
  • Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2022
  • Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2022
  • Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million US$), 2023-2028
  • Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
  • Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players
目次
Product Code: SR112023A6549

Abstract

Market Overview:

The global antisense & RNAi therapeutics market size reached US$ 1.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.

Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It regulates cell function and division and can modulate cellular responses to internal and external stresses and stimuli. It is also used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. It is employed for treating various respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. RNAi therapy also assists in preventing the production of specific genes that cause diseases or contribute to the growth of diseases.

Antisense & RNAi Therapeutics Market Trends:

The growing demand for antisense and RNAi therapeutics to treat uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis, represents one of the key factors driving the market. Besides this, there is a rise in the demand for disease management to regulate gene expression by malfunctioning genes across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, key market players are extensively investing in research and development (R&D) activities to develop molecules based on antisense technology. They are also collaborating with contract research organizations (CROs) working on drug delivery, which is strengthening the growth of the market. In addition, the growing demand for antisense RNA to prevent disease onset and reduce disease progression is positively influencing the market. Apart from this, the rising need for curing and preventing diseases, such as cancer, human immunodeficiency virus (HIV), and other diseases caused by mutating viruses is bolstering the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antisense & RNAi therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, route of administration and application.

Breakup by Technology:

RNA Interference

siRNA

miRNA

Antisense RNA

Breakup by Route of Administration:

Intravenous Route

Subcutaneous Route

Intrathecal Route

Pulmonary Delivery

Intraperitoneal Injection

Others

Breakup by Application:

Oncology

Cardiovascular Diseases (CVDs)

Respiratory Disorders

Renal Diseases

Neurodegenerative Disorders

Genetic Disorders

Infectious Diseases

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics and Sirnaomics Inc.

Key Questions Answered in This Report

  • 1. How big is the global antisense & RNAi therapeutics market?
  • 2. What is the expected growth rate of the global antisense & RNAi therapeutics market during 2023-2028?
  • 3. What are the key factors driving the global antisense & RNAi therapeutics market?
  • 4. What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
  • 5. What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
  • 6. What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
  • 7. What are the key regions in the global antisense & RNAi therapeutics market?
  • 8. Who are the key players/companies in the global antisense & RNAi therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antisense & RNAi Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 RNA Interference
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 siRNA
      • 6.1.2.2 miRNA
    • 6.1.3 Market Forecast
  • 6.2 Antisense RNA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Intravenous Route
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous Route
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intrathecal Route
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pulmonary Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intraperitoneal Injection
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Diseases (CVDs)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Respiratory Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Renal Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Neurodegenerative Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Genetic Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Infectious Diseases
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Others
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alnylam Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arbutus Biopharma Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Arrowhead Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Benitec Biopharma Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Path Holdings Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ionis Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 OliX Pharmaceuticals Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Phio Pharmaceuticals Corp.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Sarepta Therapeutics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Silence Therapeutics
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Sirnaomics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio